Publication Name	World Journal of Cardiology
Manuscript ID	68591
Country	India

Received	2021-05-27 18:41
Peer-Review Started	2021-05-27 18:45
First Decision by Editorial Office Director	2021-07-30 04:53
Return for Revision	2021-07-30 04:53
Revised	2021-08-22 01:50
Publication Fee Transferred
Second Decision by Editor	2022-01-12 03:06
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2022-01-12 21:56
Articles in Press	2022-01-12 21:56
Edit the Manuscript by Language Editor	2022-01-05 23:35
Typeset the Manuscript	2022-01-18 03:46
Publish the Manuscript Online	2022-01-19 06:37

ISSN	1949-8462 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Fondaparinux: A cornerstone drug in acute coronary syndromes
Manuscript Source	Unsolicited Manuscript
All Author List	Mohammed Yunus Khan, Chandrashekhar K Ponde, Viveka Kumar and Kumar Gaurav
Funding Agency and Grant Number
Corresponding Author	Mohammed Yunus Khan, MD, N/A, N/A, Medical Affairs, Dr.Reddy's Laboratories Ltd, Ameerpet, Hyderabad 500018, India. doctorkhan26@gmail.com
Key Words	Acute coronary syndrome; Anti-coagulant therapy; Antiplatelet therapy; Fondaparinux; Unfractionated heparin; Enoxaparin
Core Tip	The simultaneous use of antithrombotic therapy and anti-platelet therapy in the acute coronary syndrome acute phase is associated with reduced ischemic events and is more effective than either class of drug used alone. The physicians must maintain a balance while prescribing these drugs to maintain an overall benefit-risk ratio. Fondaparinux is one of the simple and effective anti-coagulant for the management of acute coronary syndrome.
Publish Date	2022-01-19 06:37
Citation	Khan MY, Ponde CK, Kumar V, Gaurav K. Fondaparinux: A cornerstone drug in acute coronary syndromes. World J Cardiol 2022; 14(1): 40-53
URL	https://www.wjgnet.com/1949-8462/full/v14/i1/40.htm
DOI	https://dx.doi.org/10.4330/wjc.v14.i1.40

Full Article (PDF)	WJC-14-40.pdf
Full Article (Word)	WJC-14-40.docx
Manuscript File	68591_Auto_Edited-YXJW-FilipodiaCL.docx
Answering Reviewers	68591-Answering reviewers.pdf
Audio Core Tip	68591-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	68591-Conflict-of-interest statement.pdf
Copyright License Agreement	68591-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	68591-Language certificate.pdf
Peer-review Report	68591-Peer-review(s).pdf
Scientific Misconduct Check	68591-Bing-Wu YXJ-2.png
Scientific Editor Work List	68591-Scientific editor work list.pdf
CrossCheck Report	68591-CrossCheck report.pdf